Enliven Therapeutics (ELVN) Preferred Stock Liabilities (2019)

Enliven Therapeutics (ELVN) reported Preferred Stock Liabilities of $77.8 million for Q4 2019, up 70.63% sequentially from $45.6 million in Q3 2019.

Enliven Therapeutics (ELVN) Preferred Stock Liabilities (2019) Analysis & Trends

Enliven Therapeutics (ELVN) has 1 years of Preferred Stock Liabilities data on file, last reported at $77.8 million in Q4 2019.

For the quarter ending Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $77.8 million; the trailing twelve-month figure through Dec 2019 stood at $77.8 million (changed N/A YoY), and the FY2019 full-year result was $77.8 million, changed N/A from the prior year.
Preferred Stock Liabilities grew to $77.8 million in Q4 2019, from $45.6 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $77.8 million in Q4 2019 to a low of $1.5 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Enliven Therapeutics	3.22 Bn	3.22 Bn	-	-

Download Data